title: Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
abstract: We investigated the relative prognostic significance of cytogenetics in 635 adult acute myeloid leukemia (AML) patients 60 years of age or older treated on front-line protocols. Classification trees and tree-structured survival analysis (TSSA) were used to identify important cytogenetic groups, and their prognostic significance was then assessed in multivariable analysis (MVA). Overall, 48.5% achieved complete remission (CR); 6.6% survived at 5 years. Complex karyotypes with at least 3 abnormalities (complex > or = 3) and a group including "rare aberrations" predicted lower CR rates (25% and 30%) versus other patients (56%). Compared with complex > or = 3, the odds of CR were significantly higher for noncomplex karyotypes without rare aberrations on MVA. Cytogenetically, complex > or = 5 predicted inferior disease-free survival on TSSA, remaining significant on MVA together with white blood cell count (WBC), sex, and age. For survival, complex > or = 5, rare aberrations, and core-binding factor (CBF) abnormalities were prognostic (P < .001), with 5-year survivals of 0%, 0%, and 19.4%, respectively, and 7.5% for remaining patients. Together with WBC, marrow blasts, sex, and age, the cytogenetic groups remained significant on MVA. In conclusion, pretreatment cytogenetics adds to other prognostic factors in older AML patients. Patients with complex > or = 5 appear to benefit minimally from current treatment and are better suited for investigational therapy or supportive care.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA. sherif.farag@osumc.edu
authors.forename: Sherif S
authors.initials: SS
authors.lastname: Farag
authors.forename: Kellie J
authors.initials: KJ
authors.lastname: Archer
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Mrózek
authors.forename: Amy S
authors.initials: AS
authors.lastname: Ruppert
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Carroll
authors.forename: James W
authors.initials: JW
authors.lastname: Vardiman
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Pettenati
authors.forename: Maria R
authors.initials: MR
authors.lastname: Baer
authors.forename: Mazin B
authors.initials: MB
authors.lastname: Qumsiyeh
authors.forename: Prasad R
authors.initials: PR
authors.lastname: Koduru
authors.forename: Yi
authors.initials: Y
authors.lastname: Ning
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mayer
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
authors.forename: Richard A
authors.initials: RA
authors.lastname: Larson
authors.forename: Clara D
authors.initials: CD
authors.lastname: Bloomfield
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007951:Leukemia, Myeloid / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome